CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has transformed the management of relapsed or refractory large B-cell lymphoma (LBCL), producing durable remissions in a subset of patients whose disease previously had few curative options. …